<DOC>
	<DOCNO>NCT01651767</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics ( body medication ) antiviral activity JNJ-47910382 administer different dosing regimen Caucasian genotype-1 chronic HCV-infected patient .</brief_summary>
	<brief_title>Study HCV-Infected Patients Determine Safety , Tolerability , Pharmacokinetics Antiviral Activity JNJ-47910382</brief_title>
	<detailed_description>This Phase Ib , double-blind ( neither physician patient know treatment patient receives ) , randomize ( study drug assign chance ) , placebo-controlled study treatment-na√Øve ( someone never use drug HCV infection ) , Caucasian genotype 1 chronic HCV-infected patient . The study consist screen period , 9-day treatment period ( 5 day actual medication intake ) 4-week follow-up period . The patient divide 4 panel 10 patient initiate sequentially . In panel patient receive JNJ-47910382 placebo 5 consecutive day . JNJ-47910382 placebo administer daily twice daily . Within panel , 5 patient genotype-1a 5 patient genotype-1b enrolled . Patients randomly assign receive active treatment placebo way 4 patient genotype receive active treatment 1 subject genotype receive placebo . The pharmacokinetic profile JNJ-47910382 assess panel . HCV RNA kinetics ( HCV RNA level ) HCV resistance study biomarkers messenger RNA ( mRNA ) , protein cell level explore . The entire study duration participant approximately four week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Chronic ( diagnosis hepatitis C 6 month screen period ) HCV infection . Geno subtype determine confirmed screening , 1a 1b Never receive ( Peg ) IFN , RBV approve investigational antiviral treatment chronic HCV infection HCV RNA level &gt; 100,000 IU/mL screening ( assessed standard quantitative vitro nucleic acid amplification assay ) Patients good accessible vein Evidence liver cirrhosis decompensated liver disease Patient coinfected HIV1 HIV2 , hepatitis A B virus infection , active tuberculosis study screen Patient infected/coinfected nongenotype1 HCV study screen Patient cardiac disease screening , active clinically significant disease , medical history physical examination finding screen Patient uncontrolled/unstable disease diabetes , epilepsy , manifest psychiatric disease , thyroid disease disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Chronic hepatitis C virus infection</keyword>
	<keyword>JNJ-47910382</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Caucasian genotype-1</keyword>
	<keyword>Non-structural protein 5A ( NS5A ) inhibitor</keyword>
</DOC>